Addressing client demand to ease the transition between clinical and commercial launch for blister products...
Addressing client demand to ease the transition between clinical and commercial launch for blister products, Almac, provider in clinical and commercial contract packaging to the global Pharmaceutical and Biotech industries, has added new blistering technology at their US commercial packaging facility in Audubon, PA
The Klockner EAS blister line can produce a range of blister formats processing both thermoform and coldform materials. This provides simple solutions for client packaging projects requiring low volume runs for evaluation of different packaging material combinations and cost effective stability packaging.
David Moore, Director of Operations at the Audubon facility explains “Almac are offering seamless services from clinical supply, packaging development / design and stability testing to final commercial pack from its two Pennsylvania sites. Clients can now easily transition from the clinical blister presentation though various development packs, with Almac providing all the associated stability services.”
The addition of a further blister line complements the already impressive array of clinical and commercial packaging capabilities of blistering, bottling, walleting and vial /ampoule labelling available at Almac.
For more information on Almac’s US packaging capabilities, please contact
[email protected]
Almac will be exhibiting at Pharma Packaging & Labeling Philadelphia 26 – 27 Feb 2014 and Interphex New York 18 – 20 March 2014.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.